| Size | 10ug |
|---|---|
| Expression Host | E.coli |
| Tag | NA |
| Molecular Weight | 18.1 KDa |
|---|---|
| Apparent Molecular Weight | 18 KDa, reducing conditions |
| Form | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
| Endotoxin Level | Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. |
|---|---|
| Activity | Immobilized Mouse ST2-His(Cat#CK89) at 5μg/ml (100 μl/well) can bind Human IL-33(Cat#C091).The ED50 of Human IL-33(Cat#C091) is 0.63 ug/ml. |
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|---|
| Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping Condition | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
| Background | Interleukin-33 (IL-33) was initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules. It is a 30-32 kD pro-inflammatory protein with intracellular and extracellular activities and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is highly and selectively expressed by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T(H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. Human IL-33 is 270 amino acids in length. |
|---|
| Product Name | Clicks |
|---|---|
| 杀螟硫磷-BSA(或OVA)抗原 | 5021 |
| 二嗪磷-BSA(或OVA)抗原 | 5140 |
| 甲基对硫磷-BSA(或OVA)抗原 | 5181 |
| 氯苯那敏-BSA(或OVA)抗原 | 5004 |
| 水胺硫磷-BSA(或OVA抗原) | 4984 |
| 泰拉霉素-BSA(或OVA)抗原 | 5194 |
| 二甲戊灵-BSA(或OVA)抗原 | 5292 |
| 腐霉利-BSA(或OVA)抗原 | 5094 |
| 甲基睾酮-BSA(或OVA)抗原 | 5166 |
| 醋酸美伦孕酮-BSA(或OVA)抗原 | 5073 |
| 硝呋烯腙-BSA(或OVA)抗原 | 5169 |
| 倍他米松-BSA(或OVA)抗原 | 5319 |
| 福莫特罗-BSA(或OVA)抗原 | 4971 |
| 替硝唑-BSA(或OVA)抗原 | 4927 |
| 布洛芬-BSA(或OVA)抗原 | 5123 |
| 地昔尼尔-BSA(或OVA)抗原 | 5095 |
| 2,4,5-三氯苯氧乙酸-BSA(或OVA)抗原 | 4821 |
| 4-氯苯氧乙酸-BSA(或OVA)抗原 | 5077 |
| 赤霉素-BSA(或OVA)抗原 | 5249 |
| 6-苄氨基嘌呤-BSA(或OVA)抗原 | 5020 |